Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
None
Protective Effects of Edaravone Dexborneol

The patients of acute ischemic stroke were divided into two groups, edaravone dexborneol treatment group and edaravone treatment group. The purpose of this study was to observe the changes of

  • 0 views
  • 22 Sep, 2021
  • 1 location
None
Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT)

are among the most important reasons of poor prognosis of acute ischemic stroke patients. The investigators speculate that a combination of argatroban, edaravone, and glucocorticoid may be helpful in

stroke
thrombectomy
argatroban
  • 0 views
  • 30 Nov, 2021
  • 1 location
None
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating ScaleRevised

primary lateral sclerosis
edaravone
  • 0 views
  • 08 Dec, 2021
  • 67 locations
None
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone

primary lateral sclerosis
edaravone
  • 0 views
  • 27 Sep, 2021
  • 48 locations
None
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.

primary lateral sclerosis
weakness
riluzole
edaravone
  • 0 views
  • 02 Dec, 2021
  • 17 locations
None
Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol

To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received endovascular thrombectomy.

  • 0 views
  • 05 Mar, 2021
  • 1 location
None
Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury

clinical trial about their efficacy and safety on patients. Since nerve growth factor and one of the antioxidative medication, edaravone, have been used in some neural diseases in clinical trials, we tend

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients

Amyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders. Pathogenically, it is characterised by loss of oxidative control, excitotoxicity due to excess glutamate and intestinal dysbiosis. In the absence of curative treatment, the aim of the study …

primary lateral sclerosis
weakness
  • 13 views
  • 16 Nov, 2021
  • 1 location
None
Radicava (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS

radicava
edaravone
  • 279 views
  • 25 May, 2021
  • 43 locations
None
COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and …

  • 0 views
  • 26 Jan, 2021
  • 1 location